Tofacitinib for the treatment of ulcerative colitis: A review of the literature
Jessica Rosenberg, Department of Internal Medicine, MedStar Georgetown University Hospital, Washington, DC 20007, United States
Joshua M Steinberg, Mark C Mattar, Department of Gastroenterology, MedStar Georgetown University Hospital, Washington, DC 20007, United States
Author contributions: Rosenberg J, Steinberg JM and Mattar MC conceived the study and drafted the manuscript; all authors approved the final version of the article.
Conflict-of-interest statement: The corresponding author has the following conflicts to disclose: Dr. Mattar reports personal fees from Pfizer, from null, during the conduct of the study; personal fees from Abbvie, from Janssen, outside the submitted work.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Mark C Mattar, MD, FACG, Academic Research, Associate Professor, Department of Gastroenterology, MedStar Georgetown University Hospital, 3800 Reservoir Road NW, Washington, DC 20007, United States. email@example.com
Telephone: +1-202-4448541 Fax: +1-877-3031462
Received: June 18, 2019
Peer-review started: June 21, 2019
First decision: July 21, 2019
Revised: August 15, 2019
Accepted: August 20, 2019
Article in press: August 20, 2019
Published online: August 31, 2019